Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results for the three months ended January 31, 2018, to take place on Monday, March 12, 2018.
Advaxis’ senior management will host a conference call to review its financial results and provide a business update. The conference call and live audio webcast will begin at 4:30 p.m. Eastern time on Monday, March 12, 2018.
Conference Call & Webcast Information
WHEN: Monday, March 12, 2018 at 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (844) 348-6133
INTERNATIONAL DIAL-IN: (631) 485-4564
CONFERENCE ID: 2588455
For those unable to participate in the live conference call or webcast, a digital recording will be available beginning March 12, 2018 two hours after the close of the conference call. To access the recording, dial (855) 859-2056 or (404) 537-3406 and provide the operator with the conference ID: 2588455. In addition, the audio webcast will be archived on the Company’s website for a period of time at ir.advaxis.com/events-presentations/events-calendar.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains integrate multiple functions into a single immunotherapy, and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and near-clinical development: HPV-associated cancers, individualized neoantigen immunotherapy, cancer-specific hotspot mutation immunotherapies and prostate cancer.